cannabinoid chewing gum

APIRx Pharmaceutical USA is developing a series of cannabinoid-based medicated chewing gums for various indications, including pain management and opioid addiction. These products are designed as combination therapies, integrating cannabinoids (such as CBD or THC) with other active pharmaceutical ingredients like opioid agonists/antagonists or gabapentin. The chewing gum delivery system is intended to provide controlled release of the active compounds and facilitate absorption through the oral mucosa, potentially improving bioavailability and providing a faster onset of action compared to traditional oral tablets. The programs are currently in the preclinical stage of development.

Other names

Cannabinoid Chewing Gum (opioid)Cannabinoid Chewing Gum (gabapentin)